Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.
You may also be interested in...
Committee Will Sift Through 'Noise' Associated With Nuplazid Efficacy
FDA is concerned the change shown by Acadia's proposed Parkinson's psychosis product may not be clinically meaningful.
Parkinson's Advisory Committee: Nuplazid Review Will Test Targeted Endpoint
Acadia's pimavanserin would be first treatment for psychosis related to Parkinson's, but it only succeeded after endpoint was refined in second Phase III trial.
Acadia Manufacturing Growing Pains Delay Pimavanserin NDA A Second Time
Company says delay is due to manufacturing scale-up work and does not reflect any change in Parkinson’s psychosis drug’s efficacy or safety profile. In tandem with the news, CEO Hacksell retired, replaced on interim basis by CFO Davis.